AIDS-Related Lymphomas Questions & Answers

1. Berhan A, Bayleyegn B, Getaneh Z. HIV/AIDS Associated Lymphoma: Review. Blood Lymphat Cancer. 2022. 12:31-45. [QxMD MEDLINE Link]. [Full Text].

2. Coté TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FJ, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer. 1997 Nov 27. 73 (5):645-50. [QxMD MEDLINE Link].

3. PDQ Adult Treatment Editorial Board. PDQ AIDS-Related Lymphoma Treatment. Cancer.gov. Available at https://www.cancer.gov/types/lymphoma/hp/aids-related-treatment-pdq#section/all. September 30, 2022; Accessed: November 12, 2022.

4. Yawetz S, Cumberland WG, van der Meyden M, Martínez-Maza O. Elevated serum levels of soluble CD23 (sCD23) precede the appearance ofacquired immunodeficiency syndrome--associated non-Hodgkin's lymphoma. Blood. 1995 Apr 1. 85 (7):1843-9. [QxMD MEDLINE Link].

5. Arvey A, Ojesina AI, Pedamallu CS, Ballon G, Jung J, Duke F, et al. The tumor virus landscape of AIDS-related lymphomas. Blood. 2015 May 14. 125 (20):e14-22. [QxMD MEDLINE Link].

6. Carbone A, Gloghini A, Bontempo D, Monini P, Tirelli U, Volpe R, et al. Proliferation in HHV-8-positive primary effusion lymphomas is associated with expression of HHV-8 cyclin but independent of p27(kip1). Am J Pathol. 2000 Apr. 156(4):1209-15. [QxMD MEDLINE Link]. [Full Text].

7. Gaidano G, Carbone A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol. 1995 Jun. 90(2):235-43. [QxMD MEDLINE Link].

8. Gaidano G, Carbone A, Pastore C, et al. Frequent mutation of the 5' noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood. 1997 May 15. 89(10):3755-62. [QxMD MEDLINE Link]. [Full Text].

9. Rabkin CS. Epidemiology of AIDS-related malignancies. Curr Opin Oncol. 1994 Sep. 6 (5):492-6. [QxMD MEDLINE Link].

10. Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol. 2003 Feb. 4(2):110-9. [QxMD MEDLINE Link].

11. Yanik EL, Achenbach CJ, Gopal S, Coghill AE, Cole SR, Eron JJ, et al. Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States. J Clin Oncol. 2016 Sep 20. 34 (27):3276-83. [QxMD MEDLINE Link].

12. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007 Jul 7. 370 (9581):59-67. [QxMD MEDLINE Link].

13. Cote TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer. 1997 Nov 27. 73(5):645-50. [QxMD MEDLINE Link]. [Full Text].

14. Mantina H, Wiggill TM, Carmona S, Perner Y, Stevens WS. Characterization of Lymphomas in a high prevalence HIV setting. J Acquir Immune Defic Syndr. 2010 Apr. 53 (5):656-60. [QxMD MEDLINE Link].

15. Biggar RJ, Engels EA, Frisch M, Goedert JJ, AIDS Cancer Match Registry Study Group. Risk of T-cell lymphomas in persons with AIDS. J Acquir Immune Defic Syndr. 2001 Apr 1. 26 (4):371-6. [QxMD MEDLINE Link].

16. Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol. 2002 Apr. 33(4):392-404. [QxMD MEDLINE Link].

17. Flinn IW, Ambinder RF. AIDS primary central nervous system lymphoma. Curr Opin Oncol. 1996 Sep. 8(5):373-6. [QxMD MEDLINE Link].

18. Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood. 2000 Dec 15. 96(13):4084-90. [QxMD MEDLINE Link]. [Full Text].

19. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009 Dec. 10 (12):1152-9. [QxMD MEDLINE Link].

20. Rabkin CS, Yang Q, Goedert JJ, Nguyen G, Mitsuya H, Sei S. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. Blood. 1999 Mar 15. 93 (6):1838-42. [QxMD MEDLINE Link].

21. D'Apuzzo M, Rolink A, Loetscher M, Hoxie JA, Clark-Lewis I, Melchers F, et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol. 1997 Jul. 27 (7):1788-93. [QxMD MEDLINE Link].

22. Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, et al. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica. 2014 Nov. 99 (11):1731-7. [QxMD MEDLINE Link].

23. Cingolani A, Cozzi Lepri A, Teofili L, Galli L, Mazzotta V, Baldin GM, et al. Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS One. 2017. 12 (10):e0186549. [QxMD MEDLINE Link]. [Full Text].

24. Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997 Feb 15. 89 (4):1413-20. [QxMD MEDLINE Link].

25. Herrlinger U, Schabet M, Clemens M, et al. Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand. 1998 Apr. 97(4):257-64. [QxMD MEDLINE Link].

26. Gabarre J, Raphael M, Lepage E, et al, for the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. Am J Med. 2001 Dec 15. 111(9):704-11. [QxMD MEDLINE Link].

27. Campeanu AT, Dumea E, Rus M, Fodor C, Ionescu AC, Mocanu E, et al. A Rare Case of Plasmablastic Lymphoma in a Patient with HIV and SARS-CoV-2 Infections. Curr Oncol. 2022 Mar 2. 29 (3):1537-1543. [QxMD MEDLINE Link]. [Full Text].

28. Clayton A, Mughal T. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy inl the post highly active antiretroviral therapy era?. Hematol Oncol. 2004 Sep. 22 (3):111-20. [QxMD MEDLINE Link].

29. Forsyth PA, DeAngelis LM. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am. 1996 Oct. 10(5):1125-34. [QxMD MEDLINE Link].

30. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005 Sep 1. 104(5):1066-74. [QxMD MEDLINE Link]. [Full Text].

31. Luoni M, Declich P, De Paoli A, et al. Bone marrow biopsy for the staging of non-Hodgkin's lymphoma: bilateral or unilateral trephine biopsy?. Tumori. 1995 Nov-Dec. 81(6):410-3. [QxMD MEDLINE Link].

32. Eisner MD, Kaplan LD, Herndier B, Stulbarg MS. The pulmonary manifestations of AIDS-related non-Hodgkin's lymphoma. Chest. 1996 Sep. 110(3):729-36. [QxMD MEDLINE Link]. [Full Text].

33. Balthazar EJ, Noordhoorn M, Megibow AJ, Gordon RB. CT of small-bowel lymphoma in immunocompetent patients and patients with AIDS: comparison of findings. AJR Am J Roentgenol. 1997 Mar. 168(3):675-80. [QxMD MEDLINE Link]. [Full Text].

34. Johnson BA, Fram EK, Johnson PC, Jacobowitz R. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol. 1997 Mar. 18(3):563-72. [QxMD MEDLINE Link]. [Full Text].

35. Re A, Cattaneo C, Rossi G. Hiv and Lymphoma: from Epidemiology to Clinical Management. Mediterr J Hematol Infect Dis. 2019. 11 (1):e2019004. [QxMD MEDLINE Link].

36. Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, et al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol. 2015 May. 26 (5):958-66. [QxMD MEDLINE Link].

37. Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, et al. Association of early HIV viremia with mortality after HIV-associated lymphoma. AIDS. 2013 Sep 24. 27 (15):2365-73. [QxMD MEDLINE Link].

38. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013 Nov 7. 122 (19):3251-62. [QxMD MEDLINE Link].

39. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial. Cancer. 2006 Apr 1. 106(7):1560-8. [QxMD MEDLINE Link]. [Full Text].

40. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003 Jun 15. 101(12):4653-9. [QxMD MEDLINE Link]. [Full Text].

41. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol. 2004 Apr 15. 22(8):1491-500. [QxMD MEDLINE Link]. [Full Text].

42. [Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell Lymphomas. NCCN. Available at https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Version 5.2022 — July 12, 2022; Accessed: November 11, 2022.

43. Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 9. 126 (2):160-6. [QxMD MEDLINE Link].

44. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013 Nov 14. 369 (20):1915-25. [QxMD MEDLINE Link].

45. Ferreri AJM, Cattaneo C, Lleshi A, Verga L, Allione B, Facchetti F, et al. A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial. Br J Haematol. 2021 Jan. 192 (1):119-128. [QxMD MEDLINE Link].

46. Noy A, Lensing SY, Moore PC, Gupta N, Aboulafia D, Ambinder R, et al. Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. Leuk Lymphoma. 2016 Jul. 57 (7):1731-4. [QxMD MEDLINE Link]. [Full Text].

47. Brunnberg U, Hentrich M, Hoffmann C, Wolf T, Hübel K. HIV-Associated Malignant Lymphoma. Oncol Res Treat. 2017. 40 (3):82-87. [QxMD MEDLINE Link]. [Full Text].

48. Jacomet C, Girard PM, Lebrette MG, et al. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS. 1997 Nov 15. 11(14):1725-30. [QxMD MEDLINE Link].

49. Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004 Jun 15. 100 (12):2627-36. [QxMD MEDLINE Link].

50. Moulignier A, Lamirel C, Picard H, Lebrette MG, Amiel C, Hamidi M, et al. Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy. Neurology. 2017 Aug 22. 89 (8):796-804. [QxMD MEDLINE Link].

51. Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019 Feb. 20 (2):216-228. [QxMD MEDLINE Link].

52. Gupta A, Sen S, Marley E, Chen W, Naina HV. Management and Outcomes of HIV-Associated Primary Effusion Lymphoma: A Single Center Experience. Clin Lymphoma Myeloma Leuk. 2016 Aug. 16 Suppl:S175-80. [QxMD MEDLINE Link].

53. Antar A, El Hajj H, Jabbour M, Khalifeh I, El-Merhi F, Mahfouz R, et al. Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature. Blood Cancer J. 2014 Mar 7. 4:e190. [QxMD MEDLINE Link].

54. Shah NN, Singavi AK, Harrington A. Daratumumab in Primary Effusion Lymphoma. N Engl J Med. 2018 Aug 16. 379 (7):689-690. [QxMD MEDLINE Link].

55. Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016 Aug 25. 128 (8):1050-8. [QxMD MEDLINE Link]. [Full Text].

56. Ramaswami R, Pria AD, Parker K, McCann S, Kanfer EJ, Nelson M, et al. Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphoma. Bone Marrow Transplant. 2016 Dec. 51 (12):1609-1611. [QxMD MEDLINE Link]. [Full Text].

57. Re A, Gini G, Rupolo M, Levis A, Bandera A, Liberati AM, et al. Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk. Bone Marrow Transplant. 2018 Feb. 53 (2):228-230. [QxMD MEDLINE Link].

58. Shindiapina P, Pietrzak M, Seweryn M, et al. Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. Front Immunol. 2021. 12:700045. [QxMD MEDLINE Link]. [Full Text].

59. Lekakis LJ, Moskowitz CH. The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy. Hemasphere. 2019 Dec. 3 (6):e295. [QxMD MEDLINE Link].

60. Johnston C, Harrington R, Jain R, Schiffer J, Kiem HP, Woolfrey A. Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 Jan. 22 (1):149-56. [QxMD MEDLINE Link]. [Full Text].

Christina Poh, MD Clinical Assistant Professor of Medicine, Division of Medical Oncology (Lymphoma), University of Washington School of Medicine

Christina Poh, MD is a member of the following medical societies: American Association for Cancer Research, American Society of Clinical Oncology, American Society of Hematology, Hemostasis and Thrombosis Research Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Incyte Morphosys<br/>Received research grant from: Incyte Morphosys.

Joseph M Tuscano, MD Associate Chief, Department of Hematology/Oncology/Internal Medicine, Veterans Administration Northern California System of Clinics; Professor, Department of Internal Medicine, Division of Hematology/Oncology, University of California, Davis, School of Medicine

Joseph M Tuscano, MD is a member of the following medical societies: American Association of Immunologists, American College of Physicians, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Mudassar Zia, MD Assistant Professor of Medicine, University of Missouri-Kansas City School of Medicine

Mudassar Zia, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Hesham M Taha, MD, FACP, MRCP(UK) Attending Physician, Department of Internal Medicine, Division of Hematology/Oncology, Nassau University Medical Center

Hesham M Taha, MD, FACP, MRCP(UK) is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Hematology, Royal College of Physicians, American Society of Clinical Oncology, Royal College of Physicians and Surgeons of Glasgow

Disclosure: Nothing to disclose.

Muhammad A Mir, MD, FACP Assistant Professor of Medicine (Hematology, Blood/Marrow Transplant) Milton S Hershey Medical Center, Pennsylvania State University College of Medicine

Muhammad A Mir, MD, FACP is a member of the following medical societies: American College of Physicians, American Society of Hematology, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Adnan A Jabbar, MD, PhD Adjunct Clinical Assistant Professor, Department of Medicine, New York College of Osteopathic Medicine of NY Institute of Technology; Fellow, Hematology and Medical Oncology, Emory University

Adnan A Jabbar, MD, PhD is a member of the following medical societies: American College of Physicians, American Medical Association, Chicago Medical Society, and Sigma Xi

Disclosure: Nothing to disclose.

Hesham M Taha, MD, FACP, MRCP(UK) Attending Physician, Department of Internal Medicine, Division of Hematology/Oncology, Nassau University Medical Center

Hesham M Taha, MD, FACP, MRCP(UK) is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, Royal College of Physicians, and Royal College of Physicians and Surgeons of Glasgow

Disclosure: Nothing to disclose.

Acknowledgments

Medscape Reference and the previous authors would like to thank the following physicians for their valuable contributions to this article: Roshan Patel, MD, Department of Pathology, Westchester Medical Center-NYMC and Kyle Bradley, MD, Department of Pathology, Emory University School of Medicine.

• Print this section
• Print the entire contents of
• Print the entire contents of article